Biotech's Wall Street malaise, Valeant's Washington woes, and immuno-oncology's primetime slot

FierceBiotech Radio

Fierce editors discuss another rough week for biotech stocks, Valeant Pharmaceuticals' doggedness in the face of congressional inquiry, and a curious new trend in pharma advertising.